Retrophin scraps nervous system disorder study, shares dive
(Reuters) – Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after…
From prison, ‘Pharma Bro’ Martin Shkreli sues ex-colleagues for $30 million
NEW YORK (Reuters) – Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, on Friday sued three…